Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 27 (11) , 1368-1375
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline Australia
- Novartis
- Actelion Pharmaceuticals
- GlaxoSmithKline
- Pfizer Australia
This publication has 27 references indexed in Scilit:
- Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registryInternational Journal of Cardiology, 2013
- Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension: Results from the Pulmonary Hypertension Registry of the United Kingdom and IrelandAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohortHeart, 2012
- Survival in pulmonary hypertension in Spain: insights from the Spanish registryEuropean Respiratory Journal, 2012
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management EraCirculation, 2010
- Pulmonary Arterial HypertensionChest, 2010
- Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equationEuropean Respiratory Journal, 2009
- An epidemiological study of pulmonary arterial hypertensionEuropean Respiratory Journal, 2007
- Pulmonary Arterial Hypertension in FranceAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991